Catalyst Pharmaceuticals Inc (STU:CN2)
€ 20.71 0.15 (0.73%) Market Cap: 2.46 Bil Enterprise Value: 2.04 Bil PE Ratio: 18.19 PB Ratio: 3.87 GF Score: 88/100

Q4 2021 Catalyst Pharmaceuticals Inc Earnings Call Transcript

Mar 17, 2022 / 12:30PM GMT
Release Date Price: €7.01 (+1.98%)
Operator

Greetings, and welcome to the Catalyst Pharmaceuticals Fourth Quarter and Full Year 2021 Results Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Ali Grande, Chief Financial Officer for Catalyst Pharmaceuticals. Thank you. You may begin.

Alicia Grande
Catalyst Pharmaceuticals, Inc. - CAO, VP, Treasurer & CFO

Good morning, everyone, and thank you for joining our conference call to discuss Catalyst's fourth quarter and full year 2021 financial results and corporate highlights. Leading the call today, we have Patrick McEnany, Chairman and Chief Executive Officer. We are also joined by Dr. Steven Miller, Chief Operating Officer and Chief Scientific Officer; and Jeffrey Del Carmen, Chief Commercial Officer. For the Q&A session, we'll also have Dr. Gary Ingenito, Chief Medical and Regulatory Officer.

Before we begin, I would like to remind you that in the following comments and in the Q&A session, we will make statements about expected future

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot